Casticin induces ovarian cancer cell apoptosis by repressing FoxM1 through the activation of FOXO3a.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

25 citing papers in PubMed, 43 citations in OpenAlex.

1. Apoptotic effect of linifanib on human ovarian cancer OVCAR3 cell line.Research in pharmaceutical sciences · 2025
   Article
2. Progress of targeted FOX family therapy in ovarian cancer.Frontiers in pharmacology · 2025
   Review
3. Research progress on FOXM1 in ovarian cancer diagnosis and therapeutics.Frontiers in oncology · 2025
   Review
4. FOXO3a-interacting proteins' involvement in cancer: a review.Molecular biology reports · 2024
   Review
5. FOXM1: A small fox that makes more tracks for cancer progression and metastasis.Seminars in cancer biology · 2023
   Review
6. Heat shock proteins and cancer: The FoxM1 connection.Biochemical pharmacology · 2023
   Review
7. Casticin as potential anticancer agent: recent advancements in multi-mechanistic approaches.Frontiers in molecular biosciences · 2023
   Review
8. Natural Products as Anticancer Agents: Current Status and Future Perspectives.Molecules (Basel, Switzerland) · 2022
   Review
9. Identification of dysregulated miRNAs-genes network in ovarian cancer: An integrative approach to uncover the molecular interactions and oncomechanisms.Cancer reports (Hoboken, N.J.) · 2020
   Article
10. The role of Anaphase Promoting Complex activation, inhibition and substrates in cancer development and progression.Aging · 2020
    Review
11. An Overview of the Potential Antineoplastic Effects of Casticin.Molecules (Basel, Switzerland) · 2020
    Review
12. FOXO3a‑SIRT6 axis suppresses aerobic glycolysis in melanoma.International journal of oncology · 2020
    Article
13. FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis.Frontiers in oncology · 2020
    Review
14. The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.Cellular oncology (Dordrecht, Netherlands) · 2019
    Article
15. Casticin-Induced Inhibition of Cell Growth and Survival Are Mediated through the Dual Modulation of Akt/mTOR Signaling Cascade.Cancers · 2019
    Article
16. Casticin inhibits breast cancer cell migration and invasion by down-regulation of PI3K/Akt signaling pathway.Bioscience reports · 2018
    Article
17. Vitex negundo and its medicinal value.Molecular biology reports · 2018
    Review
18. Inhibition of Wnt3a/FOXM1/β-Catenin Axis and Activation of GSK3β and Caspases are Critically Involved in Apoptotic Effect of Moracin D in Breast Cancers.International journal of molecular sciences · 2018
    Article
19. Casticin inhibits the epithelial-mesenchymal transition in ovarian carcinoma via the hedgehog signaling pathway.Oncology letters · 2018
    Article
20. Oncogenic regulation of tumor metabolic reprogramming.Oncotarget · 2016
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as